A ‘Missing Not at Random’ (MNAR) and ‘Missing at Random’ (MAR) Growth Model Comparison with a Buprenorphine/Naloxone Clinical Trial

ConclusionsThis performance comparison of three missing data strategies (latent growth model, Diggle‐Kenward selection model, Wu‐Carrol selection model) on sample data indicates a need for increased use of sensitivity analyses in clinical trial research. Given the potential sensitivity of the trial arm effect to missing data assumptions, it is critical for researchers to consider whether the assumptions associated with each model are defensible. (Source: Addiction)

A ‘Missing Not at Random’ (MNAR) and ‘Missing at Random’ (MAR) Growth Model Comparison with a Buprenorphine/Naloxone Clinical Trial

ConclusionsThis performance comparison of three missing data strategies (latent growth model, Diggle‐Kenward selection model, Wu‐Carrol selection model) on sample data indicates a need for increased use of sensitivity analyses in clinical trial research. Given the potential sensitivity of the trial arm effect to missing data assumptions, it is critical for researchers to consider whether the assumptions associated with each model are defensible. (Source: Addiction)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk? – Soyka M.

Opioid maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Risk of diversion and toxicity of opioid prescription drugs, including buprenorphine, causes significant concerns. This is particul… (Source: SafetyLit: All (Unduplicated))

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk? – Soyka M.

Opioid maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Risk of diversion and toxicity of opioid prescription drugs, including buprenorphine, causes significant concerns. This is particul… (Source: SafetyLit: All (Unduplicated))

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

The multi-site prescription opioid addiction treatment study: 18-month outcomes

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. (Source: Journal of Substance Abuse Treatment)

The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. (Source: Journal of Substance Abuse Treatment)

The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. (Source: Journal of Substance Abuse Treatment)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.